Gyroscope Targeting ‘Huge’ Population With Dry AMD Gene Therapy
Executive Summary
Bringing gene therapy to the masses: company raises extra £50m in series B fundraising for novel dry macular degeneration treatment
You may also be interested in...
Syncona Biotechs Face Up To Trial Delays Over COVID-19
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders
A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.